<DOC>
	<DOCNO>NCT00060268</DOCNO>
	<brief_summary>RATIONALE : Photodynamic therapy use light drug make tumor cell sensitive light kill tumor cell . Photosensitizing drug HPPH absorb tumor cell , expose light , become active kill tumor cell . PURPOSE : Phase I/II trial study effectiveness photodynamic therapy HPPH treat patient obstructive esophageal tumor .</brief_summary>
	<brief_title>Photodynamic Therapy Using HPPH Treating Patients With Obstructive Esophageal Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine , preliminarily , safety HPPH patient obstructive esophageal tumor undergo photodynamic therapy . - Determine , preliminarily , tumor response patient treated drug . - Determine length time cutaneous photosensitivity various drug dose patient . - Determine plasma clearance rate drug patient . OUTLINE : This dose-escalation study . - Phase I : Patients receive HPPH IV 1 hour day 1 . Patients undergo laser light therapy day 2 . Cohorts 3 patient receive escalate dos HPPH single light dose optimal dose determine . The optimal dose define minimum dose produce efficacy without unacceptable toxicity . - Phase II : Patients receive treatment phase I optimal dose . Patients follow monthly 6-24 month . PROJECTED ACCRUAL : A total 9-14 patient accrue study .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm esophageal cancer Stages T1T3 , N , M Tumor partially completely obstruct esophagus Primary recurrent tumor meet 1 follow criterion treatment : Patient debilitate refused conventional therapy Recurred fail respond chemotherapy , radiotherapy , surgery Deemed appropriately treat photodynamic therapy ( PDT ) opinion physician Persistent symptomatic disease require patient receive prior radiotherapy , chemotherapy , PDT photofrin HPPH Prior PDT HPPH allow tumor evident outside original treatment site No tracheal bronchial involvement bronchoscopy No T4 lesion involve aorta , lung , pericardium CT scan , MRI , endoscopic ultrasonography PATIENT CHARACTERISTICS : Age 18 Performance status Not specify Life expectancy Not specify Hematopoietic WBC least 2,000/mm^3 Platelet count least 50,000/mm^3 Hepatic Bilirubin great 3.0 mg/dL Alkaline phosphatase great 3 time upper limit normal ( ULN ) SGOT great 3 time ULN PT great 1.5 time ULN Renal Creatinine great 3.0 mg/dL Other Not pregnant Negative pregnancy test Fertile patient must use effective contraception No contraindication endoscopy No porphyria No hypersensitivity porphyrins PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics More 4 week since prior chemotherapy No concurrent chemotherapy Endocrine therapy Not specify Radiotherapy See Disease Characteristics More 4 week since prior radiotherapy No concurrent radiotherapy Surgery Not specify Other No concurrent photosensitize agent ( e.g. , tetracycline , sulfonamide , phenothiazine , sulfonylurea , hypoglycemic agent , thiazide diuretic , griseofulvin )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>recurrent esophageal cancer</keyword>
	<keyword>stage I esophageal cancer</keyword>
	<keyword>stage II esophageal cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
</DOC>